Compass Therapeutics, Inc. (CMPX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Compass Therapeutics, Inc. (CMPX) closed at USD 0.88 on 2026-10-14, a change of -78.6 % over the past year, with a market capitalization of USD 161.48M.

Compass Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Compass Therapeutics, Inc. key figures

Previous close

USD 0.88 (2026-10-14)

1-year change

-78.6 %

Market cap

USD 161.48M

Enterprise value

USD -8.76M

P/E ratio (trailing)

-2.19

P/E ratio (forward)

-1.67

EPS (trailing)

-0.41

EPS (forward)

-0.54

PEG ratio

n/a

Price to book

0.97

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.74

Employees

39

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Compass Therapeutics, Inc. and compare it with other stocks.